6Griffioen AW, Molema G. An giogenesis: potentials for pharmacologic intervention in the treatment of cancer, ~ cardiovascular diseases, and chronic inflammation [ J ]. Pharmacol Rev, 2000,52 (2) :237 - 268.
7Ribatti D. Endogenous inhibitors of angiogenesis : a histori- cal review [J]. Leuk Res,2009,33(5) :638-644.
8Steinle J J, Meininger C J, Forough R, et al. Eph 134 receptor signaling mediates endothelial cell migration and prolifera- tion via thephosphatidylinositol 3-kinase pathway [ J ]. J Biol Chem ,2002,277 (46) :43830 - 43835.
9Kim I, Ryu YS, Kwak H J, et al. EphB ligand,ephrinB2, suppresses the VEGF-and angiopoietin 1- induced Ras/ mitogen-aetivated protein kinase pathway in venous endo- thelial cells [ J ]. FASEB J,2002,16 (9) : 1126 - 1128.
10Su Z, Xu P, Ni F. Single phosphorylation of Tyr304 in the cytoplasmic tail of ephrin B2 confers high-affinity and bi- functional binding to both the SH2 domain of Grb4 and the PDZ domain of the PDZRGS3 protein [J]. Eur J Biochem, 2004,271 (9) : 1725 - 1736.
